Quarterly report pursuant to Section 13 or 15(d)

Stockholder's Equity (Details Narrative)

v3.20.2
Stockholder's Equity (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 02, 2020
Apr. 02, 2020
Feb. 07, 2020
Mar. 31, 2020
Jul. 31, 2019
Jun. 30, 2020
Jun. 30, 2020
Dec. 31, 2019
May 04, 2017
Common stock, shares authorized           50,000,000 50,000,000 45,000,000  
Common stock, par value           $ 0.0001 $ 0.0001 $ 0.0001  
Common stock, shares issued           14,282,736 14,282,736 10,404,342  
Common stock, shares outstanding           14,282,736 14,282,736 10,404,342  
Preferred stock, shares authorized            
Preferred stock, par value            
Preferred stock, shares issued            
Preferred stock, shares outstanding            
Subscription price $ 0.34 $ 0.34       $ 0.17 $ 0.17    
Warrants term 10 years 10 years       9 years 9 months 9 years 9 months    
Warrants price                 $ 0.50
Warrants exercised $ 935,000                
Convertible Preferred Stock: Series 2 [Member]                  
Preferred stock, shares authorized           1,500 1,500  
Preferred stock, par value           $ 1,000 $ 1,000 $ 1,000  
Preferred stock, shares issued           787 787  
Preferred stock, shares outstanding           787 787  
Convertible Preferred Stock: Series 1 [Member]                  
Preferred stock, shares outstanding               62,876  
Chanticleer Holdings, Inc [Member] | 2014 Stock Incentive Plan [Member]                  
Stock options granted             400,010    
Warrants price       $ 0.50          
Deemed dividend       $ 325,000          
Warrants exercised       $ 1,200,000          
Sonnet BioTherapeutics, Inc [Member]                  
Subscription price $ 0.01 $ 0.01              
Sonnet BioTherapeutics, Inc [Member] | 2014 Stock Incentive Plan [Member]                  
Warrants price 1.25 $ 1.25              
Warrants exercised   $ 350,000              
Redeemed warrants, shares   261,050              
Redeemed warrants, value   $ 66,900              
Warrants remained shares   525,554              
Convertible note agreement percentage   10.00%              
Warrant issued description   Additionally, 3,275,200 warrants were issued of which 2,925,000 warrants were issued with an exercise price ranging between $.125 and $.5 in connection with the issuance of the Company's 10% convertible note agreement and 350,000 warrants with an exercise price of $.125 were issued to the Company's bridge financing investor.              
Maximum [Member] | Securities Purchase Agreement [Member] | Convertible Preferred Stock: Series 2 [Member]                  
Common stock were issued     1,500            
Maximum [Member] | Chanticleer Holdings, Inc [Member] | 2014 Stock Incentive Plan [Member]                  
Stock price volatility       95.00%          
Risk-free interest rates       84.00%          
Weighted average term       8 years          
Maximum [Member] | Sonnet BioTherapeutics, Inc [Member] | 2014 Stock Incentive Plan [Member]                  
Warrants price 0.5 $ 0.5              
Minimum [Member] | Chanticleer Holdings, Inc [Member] | 2014 Stock Incentive Plan [Member]                  
Stock price volatility       88.00%          
Risk-free interest rates       1.70%          
Weighted average term       6 years 6 months          
Minimum [Member] | Sonnet BioTherapeutics, Inc [Member] | 2014 Stock Incentive Plan [Member]                  
Warrants price $ 1.25 $ 1.25              
2019 Rights Offering [Member]                  
Subscription price               $ 1.00  
Common stock were issued         1,894,308        
Subscription shares         $ 4,190,524        
Rights offering expiration date         Jun. 28, 2019        
Gross proceeds from rights offering         $ 6,009,733        
Outstanding debt obligations         3,075,000        
Remaining proceeds from the rights offering         $ 2,700,000        
2019 Rights Offering [Member] | Chardan Capital Markets, LLC and The Oak Ridge Financial Services Group Inc [Member]                  
Percentage of gross proceeds of rights offering         7.00%        
Reimburse expenses         $ 75,000        
Sales commission         286,000        
2019 Rights Offering [Member] | Maximum [Member]                  
Subscription shares         $ 6,084,728        
2020 Bridge Financing [Member]                  
Fair value of the derivative liability           $ 1,439,483 $ 1,439,483    
Conversion price           $ 0.50 $ 0.50    
2020 Bridge Financing [Member] | Preferred Stock: Series 2 [Member]                  
Stock issued during period conversion of convertible securities             1,400    
Percentage of cash equal to dollar value             1.25%    
Trigger default interest rate             18.00%    
Fair value of the derivative liability           $ 529,000 $ 529,000    
Increase (decrease) in derivative liabilities           $ 910,483 $ 910,483    
Conversion price           $ 1.00 $ 1.00    
Beneficial ownership percentage limitation           4.99% 4.99%    
Percentage of limitation prior to merger             9.99%    
2020 Bridge Financing [Member] | Securities Purchase Agreement [Member] | Convertible Preferred Stock: Series 2 [Member]                  
Preferred stock, shares issued       713          
Stock issued during period conversion of convertible securities       1,426,854          
2020 Bridge Financing [Member] | Chanticleer [Member] | Securities Purchase Agreement [Member] | Convertible Preferred Stock: Series 2 [Member]                  
Common stock, par value     $ 1.25            
Sale of stock, number of shares     1,500            
Gross proceeds preference stock     $ 1,500,000            
Sale of stock, transaction costs     $ 95,000            
Warrants term     5 years            
Warrants to purchase common stock     350,000            
Preferred stock value     $ 1,000            
Embedded derivative liability     529,000            
Beneficial conversion feature     $ 729,000